Effects of 23-epi-26-deoxyactein on adipogenesis in 3T3-L1 preadipocytes and diet-induced obesity in C57BL/6 mice
Jingjing Yuan,Qiangqiang Shi,Juan Chen,Jing Lu,Lu Wang,Minghua Qiu,Jian Liu
DOI: https://doi.org/10.1016/j.phymed.2020.153264
IF: 6.656
2020-09-01
Phytomedicine
Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Background</h3><p>: The ethanolic extract of <em>Actaea racemosa</em> L. (<em>Cimicifuga racemosa</em> (L.) Nutt.) has recently been reported to ameliorate obesity-related insulin resistance, hyperlipidemia, and fatty liver in rodents. However, it remains unclear which <em>A. racemosa</em> components are responsible for these beneficial effects.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Purpose</h3><p>: We aimed to examine the anti-obesity potential of 23-epi-26-deoxyactein (DA), which is contained in the ethanolic extracts of <em>A. racemosa</em>.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Study design and methods</h3><p>: To evaluate the effects of DA on adipogenesis in 3T3-L1 preadipocytes and diet-induced obesity in C57BL/6 mice, <em>in vitro</em> and <em>in vivo</em> tests were performed. For <em>in vitro</em> assessment, we used Oil red O staining that showed lipid accumulation in differentiated 3T3-L1 cells. For <em>in vivo</em> tests, male 5-week-old C57BL/6 mice were fed with low-fat diet (LFD), high-fat diet (HFD), HFD with 10 mg/kg/d luteolin (LU; positive control drug), HFD with 1 mg/kg/d DA, and HFD with 5 mg/kg/d DA for 12 weeks, respectively. Glucose and insulin tolerance tests were performed at week 17. The lipid deposition of adipose tissue and liver was visualized by hematoxylin and eosin staining. Real-time PCR showed mRNA levels of genes involved in adipogenesis, lipogenesis, and lipolysis. AMPK signaling and SIRT1-FOXO1 pathway were assessed by real-time PCR and western blot.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>: 10 μM DA and 20 μM LU treatments inhibited 3T3-L1 adipogenesis through down-regulating the expression of <em>C/ebpα, C/ebpβ</em>, and <em>Pparγ</em>, which are the critical adipogenic transcription factors. The <em>in vivo</em> results showed that 5 mg/kg/d DA and 10 mg/kg/d LU significantly lowered body weight gain, fat mass, and liver weight in HFD-fed mice. Meanwhile, DA and LU also reduced insulin resistance and serum lipoprotein levels in HFD-fed mice. Mechanistic studies showed that DA and LU promoted adipocyte lipolysis in mice through activating the AMPK signaling and SIRT1-FOXO1 pathway.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusion</h3><p>: The <em>in vitro</em> results indicate that 10 μM DA suppresses adipogenesis in 3T3-L1 preadipocytes. The <em>in vivo</em> treatment with 5 mg/kg/d DA ameliorates diet-induced obesity in mice, suggesting that DA is a promising natural compound for the treatment of obesity and related metabolic diseases.</p>
pharmacology & pharmacy,chemistry, medicinal,integrative & complementary medicine,plant sciences